I had forgotten that mild cognitive impairment (MCI) was now a definitive disease category with the FDA (in Neurology, gfp). I'm wondering why CX717 (or CX701) hasn't been mentioned by Stoll in relationship to MCI. It might be a better target than AD with a much healthier population. (This could also be considered a drawback, too.) But, I suspect, it would be much easier to recruit.
Market Data 
Markets 
AI
